Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2016 Sep 27;115(7):776-83.
doi: 10.1038/bjc.2016.249. Epub 2016 Aug 18.

Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers

Jon G Jonasson  1   2   3 , Olafur A Stefansson  4 , Oskar T Johannsson  2   5   6 , Helgi Sigurdsson  2   5 , Bjarni A Agnarsson  2   3 , Gudridur H Olafsdottir  1 , Kristin K Alexiusdottir  1   5 , Hrefna Stefansdottir  1 , Rodrigo Munoz Mitev  3 , Katrin Olafsdottir  3 , Kristrun Olafsdottir  3 , Adalgeir Arason  7 , Vigdis Stefansdottir  6 , Elinborg J Olafsdottir  1 , Rosa B Barkardottir  2   7   8 , Jorunn E Eyfjord  2   4 , Steven A Narod  9 , Laufey Tryggvadóttir  1   2
Affiliations
Comparative Study

Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers

Jon G Jonasson et al. Br J Cancer. .

Abstract

Background: The impact of an inherited BRCA2 mutation on the prognosis of women with breast cancer has not been well documented. We studied the effects of oestrogen receptor (ER) status, other prognostic factors and treatments on survival in a large cohort of BRCA2 mutation carriers.

Methods: We identified 285 breast cancer patients with a 999del5 BRCA2 mutation and matched them with 570 non-carrier patients. Clinical information was abstracted from patient charts and pathology records and supplemented by evaluation of tumour grade and ER status using archived tissue specimens. Univariate and multivariate hazard ratios (HR) were estimated for breast cancer-specific survival using Cox regression. The effects of various therapies were studied in patients treated from 1980 to 2012.

Results: Among mutation carriers, positive ER status was associated with higher risk of death than negative ER status (HR=1.94; 95% CI=1.22-3.07, P=0.005). The reverse association was seen for non-carriers (HR=0.71; 95% CI: 0.51-0.97; P=0.03).

Conclusions: Among BRCA2 carriers, ER-positive status is an adverse prognostic factor. BRCA2 carrier status should be known at the time when treatment decisions are made.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Breast cancer-specific survival probability according to ER status and the presence of a BRCA2 mutation in two time periods. (A) BRCA2 carriers diagnosed in 1935 through 1979. (B) BRCA2 carriers diagnosed in 1980 through 2012. (C) Non-carriers diagnosed in 1935 to 1979. (D) Non-carriers diagnosed in 1980 to 2012.
See this image and copyright information in PMC

References

    1. Arason A, Gunnarsson H, Johannesdottir G, Jonasson K, Bendahl PO, Gillanders EM, Agnarsson BA, Jönsson G, Pylkäs K, Mustonen A, Heikkinen T, Aittomäki K, Blomqvist C, Melin B, Johannsson OT, Møller P, Winqvist R, Nevanlinna H, Borg A, Barkardottir RB (2010) Genome-wide search for breast cancer linkage in large Icelandic non-BRCA1/2 families. Breast Cancer Res 12(4): R50. - PMC - PubMed
    1. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski R, Siolek M, Dent R, Lubinski J, Narod S (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28(3): 375–379. - PubMed
    1. Collins FS, Varmus H (2015) A new initiative on precision medicine. N Engl J Med 372(9): 793–795. - PMC - PubMed
    1. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347(16): 1233–1241. - PubMed
    1. Goodwin PJ, Phillips KA, West DW, Ennis M, Hopper JL, John EM, O'Malley FP, Milne RL, Andrulis IL, Friedlander ML, Southey MC, Apicella C, Giles GG, Longacre TA (2012) Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. J Clin Oncol 30(1): 19–26. - PubMed

Publication types

MeSH terms